HealVax GmbH is a Swiss-based biotech company committed to the development of affordable immunotherapies. The lead product of HealVax is a VLP-based vaccination against psoriasis. Waterbergh supported HealVax in Positioning and Financing.

Click here for full paper: Download

See below an interview with CEO Dr. John Foerster